Nano Dimension LTD

Nano Dimension Ltd. announced the appointment of Nadav Kidron to its Board of Directors, effective August 16, 2026, while also noting the expiration of an exclusivity period with Infinite Epigenetics, Inc. without a definitive agreement.

Nano Dimension reported a 12.1% year-over-year revenue increase to $29.0 million for Q2 2026, alongside significant improvements in gross margin and reduced net loss, while announcing the sale of MarkForged.

Nano Dimension and Murchinson have reached a settlement agreement, leading to the resignation of four directors and the appointment of three new board members, effectively reconstituting the company's leadership.

Nano Dimension announced the termination of its corporate headquarters lease, projecting approximately $25 million in cumulative net cash savings.

Nano Dimension Ltd. has entered into a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, aiming to create a Nasdaq-listed entity focused on chronic disease prediction and prevention.

Nano Dimension Ltd. has announced an extraordinary general meeting of shareholders scheduled for July 31, 2026, to vote on several proposals, including the continuation of its strategic alternatives review and amendments to its articles of association.

Nano Dimension Ltd. posted a significant net loss of $293.6 million in 2025, driven by strategic acquisitions, divestitures, and a major bankruptcy, alongside a shift to U.S. domestic issuer status.

Nano Dimension provides further details on its proposed business combination with Infinite Epigenetics, emphasizing Infinite's established science, commercial operations, and AI-driven diagnostics platform.

Nano Dimension Ltd. has entered into a non-binding term sheet to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company, aiming to create a Nasdaq-listed entity focused on AI and epigenetics.

CEO David Stehlin disposed of 19,841 ordinary shares of Nano Dimension Ltd. to satisfy tax obligations related to RSU vesting.

Nano Dimension Ltd. reports a Form 4 filing detailing share acquisition by Director Andrew Sriubas.

Nano Dimension Ltd. director Joshua Rosensweig reported the acquisition of 285,000 ordinary shares through Restricted Stock Units (RSUs) on January 1, 2026.

Director Phillip Borenstein was granted 60,000 restricted stock units in Nano Dimension Ltd. as part of the company's 2015 Stock Option Plan.

Tang Capital Management and affiliated entities have increased their beneficial ownership of Nano Dimension Ltd. to 7.9% by acquiring an additional 2,422,999 shares.

Oramed Pharmaceuticals Inc. reports changes in beneficial ownership of Nano Dimension Ltd. ordinary shares, including option and put option transactions.

Nano Dimension and Murchinson Ltd. have reached a settlement agreement, leading to the cancellation of the July 31, 2026 Extraordinary General Meeting and a reconstitution of the Company's Board of Directors.

Tang Capital Management proposes a merger with Nano Dimension, offering $1.60 per share in cash, and has acquired a 6.8% stake in the company.

Oramed Pharmaceuticals has increased its stake in Nano Dimension to 7.2% and publicly declared opposition to the company's proposed transaction with Infinite Epigenetics.

Murchinson Ltd. and affiliated shareholders have formally demanded a special meeting to replace directors and restrict the board's authority over major transactions.